Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results

Last Modified: 3/1/1997


1.		Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				no greater than 60				NCI				NU-93B1 NCI-T93-0058D, T93-0058

Last Modified: 3/1/1996


2.		Phase III Randomized Study of PIXY321 Both Before and After vs Only After ICE (IFF/CBDCA/VP-16) to Ameliorate Myelotoxicity in Patients with Previously Untreated Malignancies (Summary Last Modified 03/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				over 18				Other				YALE-HIC-7653 NCI-V94-0553

Last Modified: 10/1/1994


3.		Phase III Randomized Pilot Study of GM-CSF Alone vs G-CSF Alone vs GM-CSF/G-CSF vs PIXY321 for Mobilization of PBSC in Cancer Patients Undergoing Autologous Bone Marrow Transplantation (Summary Last Modified 10/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 18 to under 65				NCI				URCC-6492H NCI-T92-0010D, T92-0010

Last Modified: 4/13/2005


4.		Phase III Randomized Study of GM-CSF vs PIXY321 in Patients with Advanced Breast Cancer Receiving FLAC (5-FU/CF/DOX/CTX) Followed by 5 Courses of Continuous-Infusion TAX without Growth Factors (Summary Last Modified 05/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				NCI-93-C-0153I NCI-MB-318, NCI-T93-0041N, T93-0041


5.		Phase I/II Study of PIXY321 (GM-CSF/IL-3 S. cerevisiae Fusion Protein) in Combination with CTX/CBDCA in Patients with Advanced Epithelial Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 70								AECM-9202054 NCI-V92-0080

Last Modified: 7/12/2007


6.		Phase II Pilot Study of High-Dose ARA-C/DHAD with PIXY321 as Remission Induction Therapy for Relapsed/Refractory or Secondary AML, Untreated Poor-Prognosis AML, CML in Myeloid Blast Crisis, and Myelodysplastic Syndromes (Summary Last Modified 03/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 to 69				NCI				MUSC-T93-0112 NCI-T93-0112O, T93-0112

Last Modified: 3/1/1997


7.		Phase II Comparative Study of CBDCA/TAX/PIXY321 with vs without PIXY321 Prechemotherapy Hematopoietic Stimulation for Gynecologic Malignancies (Summary Last Modified 03/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MDA-DM-93083 NCI-T93-0132D, T93-0132

Last Modified: 3/1/1994


8.		Phase I Study of IL-3/GM-CSF Fusion Protein (PIXY321) and CBDCA in Patients with Advanced Cancer (Summary Last Modified 03/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Supportive care, Treatment				Completed				18 and over				NCI				BRMP-9108A NCI-92-C-0079A, NCI-T91-0213N, T91-0213

Last Modified: 12/17/2007


9.		Phase I Study of PIXY321 Following ICE (IFF/CBDCA/VP-16) in Children with Recurrent Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				1 to 21 at entry				NCI				CCG-0924 CCG-0924

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute